Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients
Status:
Completed
Trial end date:
2017-03-15
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm study, which is examining doxorubicin and cyclophosphamide
(AC) once every 2 weeks with pegteograstim support in Korean early breast cancer.